- Home
- MPV vs NTHI Comparison
MPV vs NTHI Comparison
Compare MPV & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPV | NTHI |
|---|---|---|
| Founded | 1988 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.1M | 195.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MPV | NTHI |
|---|---|---|
| Price | $19.56 | $9.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.2K | ★ 79.2K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | ★ $59,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.18 | $3.20 |
| 52 Week High | $16.42 | $25.00 |
Technical Indicators
Market Signals| Indicator | MPV | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 44.62 | 51.87 |
| Support Level | $19.50 | $8.46 |
| Resistance Level | $20.21 | $9.53 |
| Average True Range (ATR) | 0.30 | 0.95 |
| MACD | -0.04 | 0.20 |
| Stochastic Oscillator | 7.35 | 90.15 |
Price Performance
Historical ComparisonAbout MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).